Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
|
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [21] Genetic polymorphisms affecting clinical course in patients with epithelial ovarian cancer
    Kim, H. S.
    Chung, H. H.
    Kim, J. W.
    Park, N. H.
    Song, Y. S.
    Kang, S. B.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S16 - S16
  • [22] Adhesion molecules and proteases in epithelial ovarian cancers
    Cruet, S
    Carreiras, F
    Staedel, C
    Gauduchon, P
    M S-MEDECINE SCIENCES, 1999, 15 (05): : 645 - 654
  • [23] Clinical significance of NGAL and MMP-9 protein expression in epithelial ovarian cancers
    Wu, Jian
    Shang, An-Quan
    Lu, Wen-Ying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 3069 - 3075
  • [24] Genetic epidemiology of breast and ovarian cancers
    Newman, B
    Millikan, RC
    King, MC
    EPIDEMIOLOGIC REVIEWS, 1997, 19 (01) : 69 - 79
  • [25] The role of exosome heterogeneity in epithelial ovarian cancer
    Lee, Amy H.
    Koh, Ivy L.
    Dawson, Michelle R.
    ADVANCES IN CANCER BIOLOGY-METASTASIS, 2022, 4
  • [26] Heterogeneity of drug resistance in human breast and ovarian cancers
    Kern, DH
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1998, 4 (01): : 41 - 45
  • [27] BRCA penetrance for breast and ovarian cancers:: a heterogeneity study
    Hassid, S.
    Nogues, C.
    Carayol, J.
    Alarcon, F.
    Mohamdi, A.
    Labbe, M.
    Rezvani, A.
    Stoppa-Lyonnet, D.
    Berthet, P.
    Fricker, J. P.
    Andrieu, N.
    Bonaiti-Pellie, C.
    GENETIC EPIDEMIOLOGY, 2007, 31 (05) : 474 - 474
  • [28] Mutational heterogeneity in non-serous ovarian cancers
    Jamie K. Teer
    Sean Yoder
    Anxhela Gjyshi
    Santo V. Nicosia
    Chaomei Zhang
    Alvaro N. A. Monteiro
    Scientific Reports, 7
  • [29] Mutational heterogeneity in non-serous ovarian cancers
    Teer, Jamie K.
    Yoder, Sean
    Gjyshi, Anxhela
    Nicosia, Santo V.
    Zhang, Chaomei
    Monteiro, Alvaro N. A.
    SCIENTIFIC REPORTS, 2017, 7
  • [30] TreeLMM: Modelling Heterogeneity of Genetic Effects
    Moore, Rachel
    Casale, Francesco Paolo
    Barroso, Ines
    Stegle, Oliver
    GENETIC EPIDEMIOLOGY, 2016, 40 (07) : 617 - 617